How should I taper off Amitriptyline (amitriptyline)?

Multiple tablet strengths (10, 25, 50, 75 mg) and compounded liquid permit stepwise reductions. Anticholinergic rebound (cholinergic hypersensitivity) is a common discontinuation feature distinct from serotonergic withdrawal. Use available tablet strengths (10, 25, 50, 75 mg) for graduated reductions; compounded liquid supports sub-mg precision below 10 mg. Anticipate cholinergic rebound — symptoms reflect muscarinic receptor unmasking, not relapse.

Amitriptyline Tapering Guide

Q: What are the withdrawal symptoms of Amitriptyline (amitriptyline)?

Common withdrawal symptoms of Amitriptyline (amitriptyline) include: insomnia, nausea, headache, GI upset, anxiety, muscle aches. Symptom severity varies by individual, dose, and duration of use.

amitriptyline

TCAFDA 1961

Try TaperMeds

Boxed Warning

Suicidality risk in children, adolescents, and young adults under 25 during initial treatment.

Overview

Amitriptyline is a tertiary amine tricyclic antidepressant (TCA) used for major depressive disorder. It is also widely used off-label for chronic pain, migraine prophylaxis, and insomnia. It has strong anticholinergic, antihistaminic, and alpha-adrenergic blocking properties.

Common Doses

10mg, 25mg, 50mg, 75mg, 100mg

Formulations

Tablets: 10mg, 25mg, 50mg, 75mg, 100mg, 150mg

Pregnancy

Category C (risk cannot be ruled out)

Mechanism of Action

Inhibits reuptake of both serotonin and norepinephrine. Also has significant antagonist activity at histamine H1, muscarinic acetylcholine, and alpha-1 adrenergic receptors, contributing to its sedative, anticholinergic, and hypotensive effects.

Taper Notes

Multiple tablet strengths (10, 25, 50, 75 mg) and compounded liquid permit stepwise reductions. Anticholinergic rebound (cholinergic hypersensitivity) is a common discontinuation feature distinct from serotonergic withdrawal.

Maudsley Deprescribing Guidance

Use available tablet strengths (10, 25, 50, 75 mg) for graduated reductions; compounded liquid supports sub-mg precision below 10 mg. Anticipate cholinergic rebound — symptoms reflect muscarinic receptor unmasking, not relapse.

Common Withdrawal Symptoms

insomnianauseaheadacheGI upsetanxietymuscle aches

Interactions & Safety

Drug Interactions

MAOIs — contraindicated (hypertensive crisis and serotonin syndrome)
CYP2D6 inhibitors (fluoxetine, paroxetine, bupropion) significantly increase amitriptyline/nortriptyline levels
QT-prolonging drugs increase risk of arrhythmia

Food Interactions

Food does not significantly affect absorption
Grapefruit juice may increase levels via CYP3A4 inhibition
Avoid alcohol (additive CNS depression)

Contraindications

MAOIs within 14 days
Acute recovery period post-myocardial infarction
Known hypersensitivity to amitriptyline

Toxicity

Cardiotoxic in overdose (QRS widening, arrhythmias, cardiac arrest). Anticholinergic toxicity (urinary retention, delirium). Seizures. Low therapeutic index.

Pharmacokinetics

ADME Profile

Absorption

Rapidly absorbed after oral administration. Extensive first-pass metabolism; bioavailability ~30–60%. Tmax 2–5 hours.

Distribution

~6–10 L/kg

Metabolism

Hepatic via CYP2D6, CYP2C19, CYP1A2, and CYP3A4 to the active metabolite nortriptyline (via demethylation) and hydroxylated metabolites.

Elimination

Renal (primarily as metabolites). Enterohepatic recirculation contributes to variable half-life.

Protein Binding

~96%

Clearance

~46 L/hr (oral clearance, highly variable)

Build Amitriptyline taper plans in minutes

TaperMeds turns these protocols into prescriber-ready taper schedules with hyperbolic dose curves, symptom tracking, and patient handouts — for the clinicians supervising the taper.